scholarly journals Novel Cartilage Oligomeric Matrix Protein (COMP) Neoepitopes Identified in Synovial Fluids from Patients with Joint Diseases Using Affinity Chromatography and Mass Spectrometry

2014 ◽  
Vol 289 (30) ◽  
pp. 20908-20916 ◽  
Author(s):  
Emma Åhrman ◽  
Pilar Lorenzo ◽  
Kristin Holmgren ◽  
Alan J. Grodzinsky ◽  
Leif E. Dahlberg ◽  
...  
2020 ◽  
Vol 21 (6) ◽  
pp. 2155
Author(s):  
Roger Smith ◽  
Patrik Önnerfjord ◽  
Kristin Holmgren ◽  
Shacko di Grado ◽  
Jayesh Dudhia

The diagnosis of tendon injury relies on clinical signs and diagnostic imaging but imaging is subjective and does not always correlate with clinical signs. A molecular marker would potentially offer a sensitive and specific diagnostic tool that could also provide objective assessment of healing for the comparison of different treatments. Cartilage Oligomeric Matrix Protein (COMP) has been used as a molecular marker for osteoarthritis in humans and horses but assays for the protein in tendon sheath synovial fluids have shown overlap between horses affected by tendinopathy and controls. We hypothesized that quantifying a COMP neoepitope would be more discriminatory of injury. COMP fragments were purified from synovial fluids of horses with intra-thecal tendon injuries and media from equine tendon explants, and mass spectrometry of a consistent and abundant fragment revealed a ~100 kDa COMP fragment with a new N-terminus at the 78th amino-acid (NH2-TPRVSVRP) located just outside the junctional region of the protein. A competitive inhibition ELISA based on a polyclonal antibody raised to this sequence yielded more than a 10-fold rise in the mean neoepitope levels for tendinopathy cases compared to controls (5.3 ± 1.3 µg/mL (n = 7) versus 58.8 ± 64.3 µg/mL (n = 13); p = 0.002). However, there was some cross-reactivity of the neoepitope polyclonal antiserum with intact COMP, which could be blocked by a peptide spanning the neoepitope. The modified assay demonstrated a lower concentration but a significant > 500-fold average rise with tendon injury (2.5 ± 2.2 ng/mL (n = 6) versus 1029.8 ± 2188.8 ng/ml (n = 14); p = 0.013). This neo-epitope assay therefore offers a potentially useful marker for clinical use.


Rheumatology ◽  
1998 ◽  
Vol 37 (7) ◽  
pp. 721-728 ◽  
Author(s):  
K. M. Hummel ◽  
M. Neidhart ◽  
V. Vilim ◽  
N. Hauser ◽  
W. K. Aicher ◽  
...  

2001 ◽  
Vol 9 (2) ◽  
pp. 119-127 ◽  
Author(s):  
K. Misumi ◽  
V. Vilim ◽  
P.D. Clegg ◽  
C.C.M. Thompson ◽  
S.D. Carter

2015 ◽  
Vol 11 (999) ◽  
pp. 1-1
Author(s):  
Maurizio Benucci ◽  
Francesca Meacci ◽  
Mariangela Manfredi ◽  
Francesca Gobbi ◽  
Maria Infantino ◽  
...  

2008 ◽  
Vol 70 (9) ◽  
pp. 915-921 ◽  
Author(s):  
Koh ARAI ◽  
Masaaki TAGAMI ◽  
Takashi HATAZOE ◽  
Eikoh NISHIMATSU ◽  
Yuri SHIMIZU ◽  
...  

Cell Research ◽  
2021 ◽  
Author(s):  
Yi Fu ◽  
Yaqian Huang ◽  
Zhao Yang ◽  
Yufei Chen ◽  
Jingang Zheng ◽  
...  

AbstractCompelling evidence has revealed that biased activation of G protein-coupled receptor (GPCR) signaling, including angiotensin II (AngII) receptor type 1 (AT1) signaling, plays pivotal roles in vascular homeostasis and injury, but whether a clinically relevant endogenous biased antagonism of AT1 signaling exists under physiological and pathophysiological conditions has not been clearly elucidated. Here, we show that an extracellular matrix protein, cartilage oligomeric matrix protein (COMP), acts as an endogenous allosteric biased modulator of the AT1 receptor and its deficiency is clinically associated with abdominal aortic aneurysm (AAA) development. COMP directly interacts with the extracellular N-terminus of the AT1 via its EGF domain and inhibits AT1-β-arrestin-2 signaling, but not Gq or Gi signaling, in a selective manner through allosteric regulation of AT1 intracellular conformational states. COMP deficiency results in activation of AT1a-β-arrestin-2 signaling and subsequent exclusive AAA formation in response to AngII infusion. AAAs in COMP–/– or ApoE–/– mice are rescued by AT1a or β-arrestin-2 deficiency, or the application of a peptidomimetic mimicking the AT1-binding motif of COMP. Explorations of the endogenous biased antagonism of AT1 receptor or other GPCRs may reveal novel therapeutic strategies for cardiovascular diseases.


2008 ◽  
Vol 16 (11) ◽  
pp. 1413-1420 ◽  
Author(s):  
Y. Luan ◽  
L. Kong ◽  
D.R. Howell ◽  
K. Ilalov ◽  
M. Fajardo ◽  
...  

2001 ◽  
Vol 9 (7) ◽  
pp. 612-618 ◽  
Author(s):  
V. Vilı́m ◽  
R. Vytášek ◽  
M. Olejárová ◽  
S. Macháček ◽  
J. Gatterová ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document